Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)

被引：0
|
作者：
Charles E. Geyer
Hanna Bandos
Priya Rastogi
Samuel A. Jacobs
André Robidoux
Louis Fehrenbacher
Patrick J. Ward
Jonathan Polikoff
Adam M. Brufsky
Louise Provencher
Alexander H. G. Paterson
John T. Hamm
Robert L. Carolla
Luis Baez-Diaz
Thomas B. Julian
Sandra M. Swain
Eleftherios P. Mamounas
Norman Wolmark
机构：
[1] NRG Oncology,Department of Biostatistics
[2] UPMC Hillman Cancer Center,Department of Oncology
[3] University of Pittsburgh,Department of Surgery, Breast Cancer Research Group (GRCS)
[4] Magee Womens Hospital,Department of Medical Oncology
[5] Centre Hospitalier de l’Université de Montréal (CHUM),Department of Research and Evaluation – Clinical Trials
[6] Kaiser Permenente Northern California,Oncology
[7] Onoclogy/Hematology Care Clinical Trials,Department of Oncology
[8] Kaiser Permanente Southern California,Department of Medical Oncology, CCOP
[9] Centre des Maladies du Sein du CHU de Québec – Université Laval,Cancer Medicine Department of Hematology/Oncology
[10] Tom Baker Cancer Centre,Department of Surgery
[11] Norton Cancer Institute,Department of Research Development, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center
[12] Ozark Health Ventures LLC-Cancer Research for the Ozarks,Department of Surgery
[13] Puerto Rico NCORP/UPR Comprehensive Cancer Center,undefined
[14] Allegheny Health Network/Allegheny General Hospital,undefined
[15] MedStar Health,undefined
[16] Orlando Health UF Health Cancer Center,undefined
来源：
Breast Cancer Research and Treatment | 2022年 / 193卷
关键词：
Node-negative breast cancer; Anthracyclines; Duration of therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：555 / 564
页数：9
相关论文
共 49 条
  • [1] Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)
    Geyer, Charles E., Jr.
    Bandos, Hanna
    Rastogi, Priya
    Jacobs, Samuel A.
    Robidoux, Andre
    Fehrenbacher, Louis
    Ward, Patrick J.
    Polikoff, Jonathan
    Brufsky, Adam M.
    Provencher, Louise
    Paterson, Alexander H. G.
    Hamm, John T.
    Carolla, Robert L.
    Baez-Diaz, Luis
    Julian, Thomas B.
    Swain, Sandra M.
    Mamounas, Eleftherios P.
    Wolmark, Norman
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2022, 193 (03) : 555 - 564
  • [2] Correction to: Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)
    Charles E. Geyer
    Hanna Bandos
    Priya Rastogi
    Samuel A. Jacobs
    André Robidoux
    Louis Fehrenbacher
    Patrick J. Ward
    Jonathan Polikoff
    Adam M. Brufsky
    Louise Provencher
    Alexander H. G. Paterson
    John T. Hamm
    Robert L. Carolla
    Luis Baez-Diaz
    Thomas B. Julian
    Sandra M. Swain
    Eleftherios P. Mamounas
    Norman Wolmark
    [J]. Breast Cancer Research and Treatment, 2022, 193 : 565 - 565
  • [3] NSABP B-36: A randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients (pts) with node-negative breast cancer
    Samuel, Jacobs A.
    Wilson, John W.
    Bandos, Hanna
    Elledge, Richard M.
    Robidoux, Andre
    Fehrenbacher, Louis
    Ward, Patrick J.
    Polikoff, Johnathan
    Brufsky, Adam M.
    Provencher, Louise
    Paterson, Alexander H. G.
    Hamm, John T.
    Carolla, Robert L.
    Baez-Diaz, Luis
    Rastogi, Priya
    Julian, Thomas B.
    Wickerham, D. Lawrence
    Swain, Sandra M.
    Geyer, Charles E., Jr.
    Mamounas, Eleftherios P.
    Wolmark, Norman
    [J]. CANCER RESEARCH, 2015, 75
  • [4] Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer
    Ganz, Patricia A.
    Bandos, Hanna
    Geyer, Charles E.
    Robidoux, Andre
    Paterson, Alexander H. G.
    Polikoff, Jonathan
    Baez-Diaz, Luis
    Brufsky, Adam M.
    Fehrenbacher, Louis
    Parsons, Ann W.
    Ward, Patrick J.
    Provencher, Louise
    Hamm, John T.
    Stella, Philip J.
    Carolla, Robert L.
    Margolese, Richard G.
    Shibata, Henry R.
    Perez, Edith A.
    Wolmark, Norman
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2022, 192 (01) : 153 - 161
  • [5] Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer
    Patricia A. Ganz
    Hanna Bandos
    Charles E. Geyer
    André Robidoux
    Alexander H. G. Paterson
    Jonathan Polikoff
    Luis Baez-Diaz
    Adam M. Brufsky
    Louis Fehrenbacher
    Ann W. Parsons
    Patrick J. Ward
    Louise Provencher
    John T. Hamm
    Philip J. Stella
    Robert L. Carolla
    Richard G. Margolese
    Henry R. Shibata
    Edith A. Perez
    Norman Wolmark
    [J]. Breast Cancer Research and Treatment, 2022, 192 : 153 - 161
  • [6] Definitive Results of a Phase III Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Operable, Node-Positive Breast Cancer: The NSABP B-38 Trial
    Swain, Sandra M.
    Tang, Gong
    Geyer, Charles E., Jr.
    Rastogi, Priya
    Atkins, James N.
    Donnellan, Paul P.
    Fehrenbacher, Louis
    Azar, Catherine A.
    Robidoux, Andre
    Polikoff, Jonathan A.
    Brufsky, Adam M.
    Biggs, David D.
    Levine, Edward A.
    Zapas, John L.
    Provencher, Louise
    Northfelt, Donald W.
    Paik, Soonmyung
    Costantino, Joseph P.
    Mamounas, Eleftherios P.
    Wolmark, Norman
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26) : 3197 - +
  • [7] Safety analysis of the PACS 01 adjuvant trial comparing 6 cycles of FEC 100 to 3 cycles of FEC 100 followed by 3 cycles of docetaxel Taxotere® for node positive breast cancer
    Roche, H
    Spielmann, M
    Fumoleau, P
    Canon, JL
    Bravo, P
    Orfreuvre, H
    Piot, G
    Kerbrat, P
    Serin, D
    Viens, P
    Geneve, J
    Asselain, B
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S32 - S32
  • [8] Impact of treatment on quality of life (QOL) and menstrual history (MH) in the NSABP B-36: A randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide
    Ganz, Patricia A.
    Wilson, John W.
    Bandos, Hanna
    Robidoux, Andre
    Paterson, Alexander H. G.
    Polikoff, Johnathan
    Baez-Diaz, Luis
    Brufsky, Adam M.
    Fehrenbacher, Louis
    Mangalik, Aroop
    Ward, Patrick J.
    Provencher, Louise
    Hamm, John T.
    Stella, Philip J.
    Carolla, Robert L.
    Margolese, Richard G.
    Shibata, Henry R.
    Perez, Edith A.
    Wolmark, Norman
    [J]. CANCER RESEARCH, 2015, 75
  • [9] NSABP B-47: A phase III trial of adjuvant therapy comparing chemotherapy alone (six cycles of docetaxel plus cyclophosphamide or four cycles of doxorubicin plus cyclophosphamide followed by weekly paclitaxel) to chemotherapy plus trastuzumab in women with node-positive or high-risk, node-negative, HER2-low invasive breast cancer
    Fehrenbacher, Louis
    Jeong, Jong-Hyeon
    Rastogi, Priya
    Geyer, Charles E.
    Paik, Soonmyung
    Ganz, Patricia A.
    Land, Stephanie R.
    Costantino, Joseph P.
    Swain, Sandra M.
    Mamounas, Eleftherios P.
    Wolmark, Norman
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] A phase III adjuvant randomised trial of 6 cycles of 5-fluorouracil-epirubicine-cyclophosphamide (FEC100) versus 4 FEC 100 followed by 4 Taxol (FEC-T) in node positive breast cancer patients (Trial B2000)
    Delbaldo, C.
    Serin, D.
    Mousseau, M.
    Greget, S.
    Audhuy, B.
    Priou, F.
    Berdah, J. F.
    Teissier, E.
    Laplaige, P.
    Zelek, L.
    Quinaux, E.
    Buyse, M.
    Piedbois, P.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 (01) : 23 - 30
12345